Lead Product(s): Neratinib Maleate
Therapeutic Area: Oncology Product Name: Nerlynx
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2020
NERLYNX significantly reduce the ongoing risk of recurrence in HER2+ early breast cancer patients with the greatest benefit seen in women who are also HR+and who commence therapy within 12 months of completing trastuzumab-based therapy.
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 28, 2020
Novartis has entered into an agreement with Cell Therapies to manufacture Kymriah at their production facility within the Peter MacCallum Cancer Centre in Melbourne.